Is the combination of propranolol and flunarizine better than propranolol, flunarizine and amitriptyline alone in prophylaxis of migraine? An observational study at a tertiary care centre of North India

Madhumita Dixit; Abhishek K. Singh; Dwividendra K. Nim; Rakesh C. Chaurasia

doi:10.18203/2319-2003.ijbcp20243039

Authors

Madhumita Dixit Department of Pharmacology, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
Abhishek K. Singh Department of Pharmacology, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
Dwividendra K. Nim Department of Pharmacology, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
Rakesh C. Chaurasia Department of Pharmacology, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20243039

Keywords:

Efficacy, Safety, Disability, Pain, Headache

Abstract

Background: Migraine is a primary headache disorder marked by recurrent attacks of pain and associated symptoms. Propranolol is traditionally considered highly effective for migraine prophylaxis, but other drugs have recently shown promise.

Methods: This study was a prospective, observational, randomized, parallel-arm, unicentric trial conducted in the neurology department of a tertiary care hospital in North India. Patients with migraine without aura were randomly assigned to one of four treatment groups. After obtaining consent, patients were randomized using a random number table. Group 1 received propranolol (80 mg), group 2 received flunarizine (10 mg), group 3 received a combination of propranolol (40 mg) and flunarizine (10 mg), and group 4 received amitriptyline (10 mg) daily. The primary outcome was a change in the frequency of migraine days, while secondary outcomes included changes in moderate-to-severe headache days and disability levels.

Results: The combination of propranolol (40 mg) and flunarizine (10 mg) was significantly more effective in reducing the frequency of migraine attacks at the end of 3 months compared to the group receiving amitriptyline (10 mg). However, no significant differences between the groups were observed at baseline, 1 month, and 2 months. For other outcomes, including adverse drug reactions (ADRs), there were no significant differences between the groups.

Conclusions: The combination of propranolol (40 mg) and flunarizine (10 mg) demonstrated superior efficacy over amitriptyline (10 mg) after prolonged treatment, while its effectiveness was comparable to other groups at earlier time points. ADRs were similar across all groups.

Metrics

Metrics Loading ...

References

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia: Int J Headache. 2018;38(1):1-211.

Burstein R NR, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619-29.

Ray BK, Paul N, Hazra A, Das S, Ghosal MK, Misra AK, et al. Prevalence, burden, and risk factors of migraine: A community-based study from Eastern India. Neurol India. 2017;65(6):1280-8.

Harrison's principles of internal medicine. 20th edition / ed. Jameson JL KD, Longo DL, Fauci AS, Hauser SL, Loscalzo J, editors. New York: McGraw-Hill Education. 2018.

Mehrotra S, Gupta S, Chan KY, Villalón CM, Centurión D, Saxena PR, et al. Current and prospective pharmacological targets in relation to antimigraine action. Naunyn-Schmiedeberg's Arch Pharmacol. 2008;378(4):371-94.

Methodology WHOIWGfDS MW, Research WHOCCfDU, Clinical Pharmacological S. Introduction to drug utilization research. Geneva: World Health Organization. 2003.

Diener HCTC, Dodick DW, Silberstein SD, Lipton RB, Ashina M. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019;39(6):687-710.

Benzon HTRS, Liu SS, Fishman S, Cohen SP, Hurley RW. Essentials of Pain Medicine: Elseiver. 2017.

Zandifar AAF, Haghdoost F, Masjedi SS, Manouchehri N, Banihashemi M, Ghorbani A, et al. Reliability and validity of the migraine disability assessment scale among migraine and tension type headache in Iranian patients. Biomed Res Int. 2014;2014:978064.

Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999;53(5):988-94.

Zaki SA. Adverse drug reaction and causality assessment scales. Lung India. 2011;28(2):152-3.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Demirkaya S, Dora B, Topcuoglu M, Ulas U, Vural O. A comparative study of magnesium, flunarizine and amitriptyline in the prophylaxis of migraine. J Headache Pain. 2000;1:179-86.

Bordini CA, Arruda MA, Ciciarelli MC, Speciali JG. Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. a double-blind trial. Arq Neuro-Psiquiatria. 1997;55:536-41.

Shimell CJ, Fritz VU, Levien SL. A comparative trial of flunarizine and propranolol in the prevention of migraine. South Afr Med J. 1990;77(2):75-7.

Ludin H-P. Flunarizine and Propranolol in the Treatment of Migraine. Headache. 1989;29(4):219-24.